So the other drug is off patent meaning that there are no royalties to be paid for a combo therapy -- or, that the original patent holder of the other drug will be anxious to strike a deal for Kevetrin so that they can put out "Docetaxel Plus" combo drug with Kevetrin, to get something back under patent again.

And I was just reading about Sanofi needing to increase its product pipeline.